Orlando joins Alcresta with more than 18 years of experience in executive roles leading organizations through rapid growth while successfully developing and launching therapeutics and biologics.
Prior to joining Alcresta, Daniel was chief operating officer at Vericel Corp., where during his tenure he led every function of the cell therapy company, most recently, the Commercial, Manufacturing, Engineering and R and D organisations.
Previously, Orlando held executive positions in Business Development, Marketing and Sales with Takeda as well as similar developmental roles at Abbott Laboratories.
Alcresta Therapeutics is focused on developing and commercialising novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases.
Alcresta currently markets RELiZORB for enterally fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer and pancreatitis, and is developing platform applications for patients with short bowel syndrome and prematurely born infants treated in the NICU.
Alcresta Therapeutics, Inc. is backed by top-tier investors: Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners, and Third Rock Ventures.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera